OS Cancer Research Results
OS, overall survival: Click to Expand ⟱
| Source: |
| Type: |
Overall survival
|
Scientific Papers found: Click to Expand⟱
Risk∅, In this study, over a median of 8.6 years, LDA was not associated with incident cancer among older adults, but cancer mortality risk was significantly elevated.
OS∅, However, the elevated cancer mortality risk seen with aspirin for participants in the RCT period did not persist into the post-RCT observation period, suggesting no legacy effect.
Dose↝, 1550 participants with resected non-metastatic colorectal cancer from 11 countries or territories in Asia-Pacific and the Middle East were randomly assigned to receive daily aspirin 200 mg or placebo for 3 years.
OS∅, No significant differences were observed in 5-year disease-free survival or overall survival between the aspirin and placebo groups, with hazard ratios (HRs) of 0·91 (95% CI 0·73–1·13) for disease-free survival and 0·75 (0·53–1·07) for os
QoL↑, Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study
OS∅,
OS∅, Huachansu when combined with gemcitabine did not improve the outcome of patients with locally advanced and/or metastatic pancreatic cancer.
other∅, No significant difference in disease progression was noted between the two groups at days 14 (p=0.33), 28 (p=0.67) or 56 (p=0.50).
OS∅, There was no difference in survival between both groups from study entry to censor date (p=0.38).
other∅, In this substudy analysis, treatment with CBD oil did not affect disease progression or survival over the course of 56 days in patients with advanced cancer.
OS↑, a strong and significant inverse association was observed between bladder cancer mortality and broccoli intake
OS∅, There were no significant associations for total vegetables, total fruits, or other individual cruciferous vegetables.
OS∅, clinical trial of 88 patients with recurrent glioblastoma, the addition of disulfiram and copper to alkylating chemotherapy did not significantly improve survival at 6 months,
toxicity↑, Six patients (15%) in the experimental group developed elevated liver enzymes compared with no patient in the SOC group
QoL↑, Patients in the melatonin-treated group had better adjusted HRQoL scores, with a slightly significantly better score (2.69 points, 95% confidence interval (CI)=0.01-5.38, p=0.049) being found in social well-being
OS∅, Median survival was 7.3 months (95% CI=3.42-11.14) without significant difference (lower survival in placebo group)
selectivity↑, A great amont of DNA damage marker was observed in the placebo-treated group, and this was associated with lower survival (r(2)=-0.656, p=0.02), implying the protective effect of melatonin in healthy cells.
Showing Research Papers: 1 to 8 of 8
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8
Pathway results for Effect on Cancer / Diseased Cells:
Transcription & Epigenetics ⓘ
other∅, 2,
Drug Metabolism & Resistance ⓘ
Dose↝, 1, selectivity↑, 1,
Functional Outcomes ⓘ
OS↑, 1, OS∅, 8, QoL↑, 2, Risk∅, 1, toxicity↑, 1,
Total Targets: 8
Pathway results for Effect on Normal Cells:
Total Targets: 0
Scientific Paper Hit Count for: OS, overall survival
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:229 State#:% Dir#:6
wNotes=on sortOrder:rid,rpid
Home Page